CSL announces acquisition of CytoGam® from MedImmune

CSL announces acquisition of CytoGam® from MedImmune

Melbourne, Australia — 09/11/2006

Melbourne, Australia: - CSL Limited has announced that its subsidiary, ZLB Behring, has reached an agreement with MedImmune, Inc. to acquire CytoGam®, (cytomegalovirus immune globulin intravenous (human)) and related assets. CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV), which is indicated for prophylaxis against CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is the most common cause of infection occurring after any solid organ transplant, contributing significantly to morbidity and mortality in organ
transplant recipients.

CSL advised that ZLB Behring will acquire CytoGam for US$120 million in cash, US$70 million of which is subject to achievement of sales milestones.

“CytoGam fits well in ZLB Behring’s immunoglobulin portfolio.” said Peter Turner, president of ZLB Behring. “We are proud of our heritage of providing a reliable, quality supply of critical therapies to small patient populations. We look forward to continuing
that heritage with transplant patients.”

The acquisition includes CytoGam and related assets, including patents and trademarks, manufacturing contracts and government authorisations associated with the product. No employees will transfer to ZLB Behring from MedImmune.

Merrill Lynch acted as advisers to CSL on this transaction.

Download this release: PDF icon CSL announces acquisition of CytoGam® from MedImmune

For further information please contact:

Media Contacts
Australia and New Zealand
Dr Rachel David
Director of Public Affairs
Phone: 0401 775 779

Investor Contact

 Mark Dehring
 Director of Investor Relations
 Phone: +61 3 9389 2818
© 2017 CSL Limited